Clinical trials: Hematologic Malignancies
Acute Myeloid Leukemia, Minimal Residual Disease
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
This is a interventional, transplantation study. The procedure under study is the infusion of alloreactive NK cells in adult AML patients, eligible for ASCT, who achieved CR after conventional chemotherapy, but harbor…
- Conditions
- Acute Myeloid Leukemia, Minimal Residual Disease, Natural Killer Cell
- Trial name
- NCT06885476
- Testing
- Infusion of alloreactive NK cells
- Where
- Italy
- Volunteers
- 22 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematologic Malignancy, Acute Leukemia
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia
- Trial name
- NCT05735717
- Testing
- Fludarabine, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Lymphoproliferative Diseases
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.
- Trial name
- NCT00124189
- Testing
- GRN163L
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Geron Corporation
Chronic Myeloid Leukemia (CML), Chronic Phase
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Primary objective : To identify epigenetic dysregulations of in vivo TKI-resisting CML cells Hypothesis : An epigenetic dysregulation is involved in the in vivo survival of a CML cell subclone despite the use of TKIs
- Trial name
- EPIK (NCT03481868)
- Testing
- Collection of blood and bone marrow
- Where
- 16 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acute Lymphoblastic Leukemia
Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia
the goal of this observational study is Assesment of systemic inflammatory index (SII) , system inflammation response index (SIRI) and CRP Albumin ratio(CAR) as biomarkers for ALL prognosis.
- Trial name
- NCT06674850
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hematopoietic and Lymphoid Cell Neoplasm, Lung Non-Small Cell Carcinoma
Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
This trial evaluates the risk of chemotherapy toxicity in older patients with blood cancer or non-small cell lung cancer. The purpose of this study is to describe a patient's wellness before and after chemotherapy treatment.
- Trial name
- NCT05106374
- Testing
- Biospecimen Collection, Cognitive Assessment, Physical Performance Testing
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
Adult patients with a confirmed diagnosis of symptomatic and relapsed and/or refractory MM, after receiving bortezomib, lenalidomide and daratumumab during first and second lines, will be eligible to be enrolled in this study.
- Trial name
- IPoD-790 (NCT04790474)
- Testing
- ixazomib-pomalidomide-dexamethasone
- Where
- 7 sites in Israel
- Volunteers
- 61 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is…
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
- Trial name
- NCT04872790
- Testing
- Dasatinib, Methotrexate, Prednisone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML
This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML). The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to…
- Trial name
- NCT06536010
- Testing
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-28；
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Xiaotian
Chronic Lymphocytic Leukemia
B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression
B type chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the western world. It is a disease that occurs primarily in aging individuals and occurs more frequently in males than females.
- Trial name
- NCT01030913
- Where
- United States
- Volunteers
- 1,248 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Neutropenia, Breast Cancer
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of…
- Trial name
- ADVANCE (NCT02643420)
- Testing
- SPI-2012, Pegfilgrastim, Docetaxel
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 406 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Acute Lymphoblastic Leukemia, Cancer
PACE CALL: Weight Loss Study for Childhood Leukemia Survivors
UC San Diego researchers conducted a study to develop and evaluate an internet and text message based weight loss study for childhood acute lymphoblastic leukemia (ALL) survivors.
- Conditions
- Acute Lymphoblastic Leukemia, Cancer, Obesity
- Trial name
- NCT01253720
- Testing
- PACE CALL/Fit4Life
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Huang, Jeannie, M.D.
Chronic Lymphocytic Leukemia
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the safety of GCS-100 and the biologic activity of GCS-100 in subjects with chronic lymphocytic leukemia.
- Trial name
- PR-CS008 (NCT00514696)
- Testing
- GCS-100
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- La Jolla Pharmaceutical Company
Multiple Myeloma, Patient Reported Outcome (PRO)
Digital Support for Multiple Myeloma Quality of Life
The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.
- Conditions
- Multiple Myeloma, Patient Reported Outcome (PRO), Supportive Care in Cancer, Quality of Life
- Trial name
- DigiMyQoL (NCT07642362)
- Testing
- Digital support
- Where
- Greece
- Volunteers
- 108 people
- Sponsor
- CareAcross
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia.
- Conditions
- Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT05038592
- Testing
- Decitabine, Tagraxofusp-erzs
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
LGL Leukemia, CTCL
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed…
- Trial name
- NCT03239392
- Testing
- BNZ132-1-40
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bioniz Therapeutics
Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Blood disorders such as leukemia or lymphoma or hemoglobinopathies can benefit from receiving an allogeneic (meaning that the cells are from a donor) stem cell transplant. Stem cells are created in the bone marrow.
- Conditions
- Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00579111
- Testing
- Campath, Busulfan, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
AML/MDS, CMML
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with…
- Conditions
- AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04139434
- Testing
- LP-108, LP-108 and azacitidine
- Where
- 7 sites in United States, Spain
- Volunteers
- 32 people
- Sponsor
- Newave Pharmaceutical Inc
Leukemia
AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia
RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young…
- Trial name
- NCT01431664
- Testing
- multikinase inhibitor AT9283, laboratory biomarker analysis, pharmacological study
- Where
- 5 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Cancer Research UK
Leukemia
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01505699
- Testing
- RNA analysis, cytogenetic analysis, microarray analysis
- Volunteers
- 186 people
- Sponsor
- Eastern Cooperative Oncology Group